Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized monoclonal antibody 3S193 (90Y-hu3S193) in patients with advanced ovarian cancer
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Monoclonal antibody 3S193 (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Adverse reactions
- 16 Aug 2005 New trial record.